A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

Summary

The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind, placebo-controlled, parallel-group comparison in order to determine the clinical dose of TAK-272.

Timeline

Start

2014-10-16

Primary completion

2016-08-18

Completion

2016-08-18

Outcome

Met primary endpoint

registry Placebo vs TAK-272 5 mg; p <0.0001; LS Mean difference -0.325 (95% CI -0.4845 to -0.1649); ANCOVA NCT02332824 ↗

Publications

• Wang GM, Li LJ, Fan L, Xu M, Tang WL, Wright JM. Renin inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2025 Feb 27;2(2):CD012570. doi: 10.1002/14651858.CD012570.pub2.

Drugs

Indications